Nantkwest Inc.

Immunitybio, Inc.

Nantcell, Inc.

Nant Holdingsip, LLC

Institute for Cancer Research

Barry J Simon

Hans G Klingemann

Laurent H Boissel

Tien Lee

Patrick Soon-Shiong

Kayvan R Niazi

Shahrooz Rabizadeh

Stephen Charles Benz

Kerry S Campbell

This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Genetically modified NK-92 cells having a safety switch

Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

Tumoricidal and antimicrobial compositions and methods

Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

Nant cancer vaccine

Detection of under-expression of selected genes in NK cells is used to confirm a hypoxic tumor microenvironment that is ordinarily suppressive with respect to ADCC and cytotoxic cell killing of NK cells. Most notably, while hypoxia is known to upregulate HIF-1&#x3b1; and genes under the control of HIF-1&#x3b1;, hypoxia in a tumor microenvironment led to under-expression of selected genes, including HIF-1&#x3b1;. Thus, gene expression analysis of certain genes on NK cells can be used to detect conditions in a tumor that would indicate use of haNK cells.

Hypoxic NK cells and methods therefor

Coordinated multi-prong cancer therapy

Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer

Tumoricidal and antimicrobial composition

Growing community of inventors

Culver City, CA, United States of America

Barry J Simon